NCT02582242View on ClinicalTrials.gov

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

PHASE4CompletedINTERVENTIONAL
Enrollment

437

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

March 18, 2017

Study Completion Date

April 18, 2017

Conditions
DiabetesType 2 Diabetes Mellitus
Interventions
DRUG

biphasic insulin aspart 30

Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.

Trial Locations (50)

114

Novo Nordisk Investigational Site, Taipei

407

Novo Nordisk Investigational Site, Taichung

813

Novo Nordisk Investigational Site, Kaohsiung City

11217

Novo Nordisk Investigational Site, Taipei

16000

Novo Nordisk Investigational Site, Algiers

16049

Novo Nordisk Investigational Site, Algiers

16059

Novo Nordisk Investigational Site, Bursa

31000

Novo Nordisk Investigational Site, Oran

34093

Novo Nordisk Investigational Site, Istanbul

34390

Novo Nordisk Investigational Site, Istanbul

46000

Novo Nordisk Investigational Site, Kahramanmaraş

46002

Novo Nordisk Investigational Site, Ternopil

49005

Novo Nordisk Investigational Site, Dnipro

79010

Novo Nordisk Investigational Site, Lviv

100029

Novo Nordisk Investigational Site, Beijing

100071

Novo Nordisk Investigational Site, Beijing

100144

Novo Nordisk Investigational Site, Beijing

100191

Novo Nordisk Investigational Site, Beijing

100730

Novo Nordisk Investigational Site, Beijing

110088

Novo Nordisk Investigational Site, New Delhi

116011

Novo Nordisk Investigational Site, Dalian

130021

Novo Nordisk Investigational Site, Changchun

200072

Novo Nordisk Investigational Site, Shanghai

200240

Novo Nordisk Investigational Site, Shanghai

210011

Novo Nordisk Investigational Site, Nanjing

210012

Novo Nordisk Investigational Site, Nanjing

210029

Novo Nordisk Investigational Site, Nanjing

212001

Novo Nordisk Investigational Site, Zhenjiang

213003

Novo Nordisk Investigational Site, Changzhou

214023

Novo Nordisk Investigational Site, Wuxi

215006

Novo Nordisk Investigational Site, Suzhou

230001

Novo Nordisk Investigational Site, Hefei

300052

Novo Nordisk Investigational Site, Tianjin

330006

Novo Nordisk Investigational Site, Nanchang

350001

Novo Nordisk Investigational Site, Fuzhou

404000

Novo Nordisk Investigational Site, Chongqing

510515

Novo Nordisk Investigational Site, Guangzhou

518035

Novo Nordisk Investigational Site, Shenzhen

530002

Novo Nordisk Investigational Site, Visakhapatnam

560002

Novo Nordisk Investigational Site, Bangalore

560038

Novo Nordisk Investigational Site, Bangalore

570001

Novo Nordisk Investigational Site, Mysore

610071

Novo Nordisk Investigational Site, Chengdu

700080

Novo Nordisk Investigational Site, Kolkata

781006

Novo Nordisk Investigational Site, Guwahati

050000

Novo Nordisk Investigational Site, Shijiazhuang

Unknown

Novo Nordisk Investigational Site, Shatin, New Territories

625 020

Novo Nordisk Investigational Site, Madurai

01130

Novo Nordisk Investigational Site, Adana

01004

Novo Nordisk Investigational Site, Kiev

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY